Supernus Pharmaceuticals, Inc. - Common Stock - Çeyreklik Finansal İstatistikler (NASDAQ:SUPN) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit 44.41 M30.6 M58.53 M-61.66 M19.86 M66.52 M 83.26 M Yatırım faaliyetlerinden elde edilen nakit -12.64 M37.32 M-30.61 M48.71 M-51.31 M-19.22 M -52.43 M Finansman faaliyetlerinden elde edilen nakit 5.89 M-21.4 M935 K21.07 M8.53 M9.12 M 39.64 M Serbest nakit akışı 44.41 M30.6 M58.08 M-61.79 M19.43 M66.52 M 82.25 M

Haberler

Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS)

Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?

Supernus Pharmaceuticals 33,4 milyon dolarlık ödeme yapacak

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates

Bausch Health (BHC) Lags Q1 Earnings Estimates

Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen Walloped Wall Street's First Quarter Views; Here's What Happened

BofA, Supernus Pharmaceuticals için hisse hedefini düşürdü

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?